CN1954870A - 一种由肿节风和白花蛇舌草制成的药物组合物 - Google Patents
一种由肿节风和白花蛇舌草制成的药物组合物 Download PDFInfo
- Publication number
- CN1954870A CN1954870A CN 200610142637 CN200610142637A CN1954870A CN 1954870 A CN1954870 A CN 1954870A CN 200610142637 CN200610142637 CN 200610142637 CN 200610142637 A CN200610142637 A CN 200610142637A CN 1954870 A CN1954870 A CN 1954870A
- Authority
- CN
- China
- Prior art keywords
- extract
- herba
- hedyotidis diffusae
- herba hedyotidis
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002131 composite material Substances 0.000 title abstract description 5
- 241000157511 Oldenlandia Species 0.000 title abstract 2
- 241000736026 Sarcandra Species 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 64
- 239000000284 extract Substances 0.000 claims description 173
- 239000008194 pharmaceutical composition Substances 0.000 claims description 84
- 238000002360 preparation method Methods 0.000 claims description 62
- 239000007924 injection Substances 0.000 claims description 51
- 238000002347 injection Methods 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 51
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 239000000890 drug combination Substances 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 13
- 239000001530 fumaric acid Substances 0.000 claims description 11
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 11
- HOEVRHHMDJKUMZ-UHFFFAOYSA-N Isofraxidin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2OC HOEVRHHMDJKUMZ-UHFFFAOYSA-N 0.000 claims description 10
- ANCHXLMTFNOVDK-UHFFFAOYSA-N Isofraxidin Natural products COC1=C(O)C(OC)=CC2=C1OC=CC2=O ANCHXLMTFNOVDK-UHFFFAOYSA-N 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 7
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 5
- 235000001671 coumarin Nutrition 0.000 claims description 5
- 150000004775 coumarins Chemical class 0.000 claims description 5
- 229930003944 flavone Natural products 0.000 claims description 5
- 235000011949 flavones Nutrition 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 150000002213 flavones Chemical class 0.000 claims description 4
- 150000007524 organic acids Chemical group 0.000 claims description 4
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 82
- 201000011510 cancer Diseases 0.000 abstract description 16
- 201000007270 liver cancer Diseases 0.000 abstract description 12
- 208000014018 liver neoplasm Diseases 0.000 abstract description 12
- 240000004274 Sarcandra glabra Species 0.000 abstract description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 abstract description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 4
- 206010017758 gastric cancer Diseases 0.000 abstract description 4
- 206010038038 rectal cancer Diseases 0.000 abstract description 4
- 201000001275 rectum cancer Diseases 0.000 abstract description 4
- 201000011549 stomach cancer Diseases 0.000 abstract description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 3
- 201000010881 cervical cancer Diseases 0.000 abstract description 3
- 210000002751 lymph Anatomy 0.000 abstract description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 108
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- 239000000243 solution Substances 0.000 description 51
- 229940090044 injection Drugs 0.000 description 50
- 241000699670 Mus sp. Species 0.000 description 41
- 238000012360 testing method Methods 0.000 description 35
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 31
- 229960004397 cyclophosphamide Drugs 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
- 230000000694 effects Effects 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 28
- 238000002512 chemotherapy Methods 0.000 description 25
- 230000002401 inhibitory effect Effects 0.000 description 25
- 229940079593 drug Drugs 0.000 description 22
- 238000005516 engineering process Methods 0.000 description 22
- 239000000706 filtrate Substances 0.000 description 22
- 239000007788 liquid Substances 0.000 description 21
- 239000008187 granular material Substances 0.000 description 20
- 239000013641 positive control Substances 0.000 description 20
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 18
- 239000008215 water for injection Substances 0.000 description 18
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 17
- 229920000053 polysorbate 80 Polymers 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 239000002775 capsule Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 239000003826 tablet Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 229920002472 Starch Polymers 0.000 description 12
- 238000004321 preservation Methods 0.000 description 12
- 239000008107 starch Substances 0.000 description 12
- 235000019698 starch Nutrition 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000013558 reference substance Substances 0.000 description 8
- 239000011265 semifinished product Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 238000001694 spray drying Methods 0.000 description 8
- 241000700199 Cavia porcellus Species 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 229960002949 fluorouracil Drugs 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000007689 inspection Methods 0.000 description 7
- 239000008602 kang-lai-te Substances 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 238000005325 percolation Methods 0.000 description 7
- 239000008354 sodium chloride injection Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 240000002853 Nelumbo nucifera Species 0.000 description 6
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 6
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000012567 medical material Substances 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 6
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 6
- 235000005493 rutin Nutrition 0.000 description 6
- 229960004555 rutoside Drugs 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000008227 sterile water for injection Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 240000001659 Oldenlandia diffusa Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- -1 mouth paster Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- 239000003549 soybean oil Substances 0.000 description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000007766 cera flava Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000005262 decarbonization Methods 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229940023488 pill Drugs 0.000 description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000009287 sand filtration Methods 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 239000008347 soybean phospholipid Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 239000010297 uvangoletin Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 201000005619 esophageal carcinoma Diseases 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 239000013505 freshwater Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229960003943 hypromellose Drugs 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011046 pyrogen test Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000011003 system suitability test Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000758719 Chloranthaceae Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000003146 Lobelia chinensis Species 0.000 description 1
- 241000607292 Maguireothamnus speciosus Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 244000085660 Peristrophe bivalvis Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 235000010842 Sarcandra glabra Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000691803 Urobatis jamaicensis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229940081995 fluorouracil injection Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940087332 rutin 10 mg Drugs 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 提取物配比 | 提取物重量配比(肿提+白提:mg+mg) | 瘤重(g) | 抑瘤率(%) |
空白对照组康莱特注射液组肿节风提取物组白花蛇舌草提取物组 | ---- | 2.56±0.981.02±0.46**#△1.98±0.75*1.88±0.80* | -60.1626.5622.66 | |
本发明药物组合物组(肿节风提取物+白花蛇舌草提取物) | (1∶0.01)(1∶0.02)(1∶0.025)(1∶0.03)(1∶0.05)(1∶0.06)(1∶0.65)(1∶0.07)(1∶0.075)(1∶0.1)(1∶0.13)(1∶0.15)(1∶0.2)(1∶0.3)(1∶0.325)(1∶0.43)(1∶0.5) | 1000+101000+20400+10300+10200+101000+60200+130300+20400+30300+301000+130200+30300+60200+60400+130300+130300+150 | 1.32±0.82**1.44±0.69**1.34±0.68**1.11±0.83**#△1.48±0.64**1.16±0.76**#△1.28±0.77**#△0.98±0.44**##△△1.37±0.77**1.06±0.93**#△1.37±0.83**1.45±0.82**1.23±0.67**#△1.30±0.49**#△1.25±0.76**#△1.18±0.63**#△1.15±0.27**#△ | 52.2755.1458.6360.9366.9266.7267.1968.5464.9863.4664.2263.5863.9864.5262.3761.3358.72 |
组别 | 药材配比 | 重量配比(g) | 给药剂量(mg/kg) | 瘤重(g) | 抑瘤率(%) |
空白对照组阳性对照组肿节风组白花蛇舌草组 | ---- | -50140140 | 2.42±0.540.78±0.08**1.34±0.27**1.44±0.30* | -69.8240.3635.42 | |
本发明药物组合物组(肿节风+白花蛇舌草) | (1∶0.02)(1∶0.04)(1∶0.05)(1∶0.07)(1∶0.1)(1∶0.13)(1∶0.2)(1∶0.3)(1∶0.6)(1∶0.75)(1∶1)(1∶1.2)(1∶1.5)(1∶2)(1∶3)(1∶4)(1∶6) | 50+150+220+115+120+215+210+250+1550+3020+1515+1550+6020+3015+3020+6015+6010+60 | 140140140140140140140140140140140140140140140140140 | 0.95±0.11**#△0.91±0.56**#△0.88±0.84**#△0.86±0.20**#△0.78±0.06**#△0.76±0.37**#△0.77±0.20**#△0.79±0.14**#△0.80±0.29**#△0.81±0.07**#△0.82±0.18**#△0.83±0.68**#△0.83±0.99**#△0.84±0.67**#△0.85±0.77**#△0.86±0.54**#△0.88±0.12**#△ | 43.4448.7547.6650.6452.1961.6958.0056.7254.4853.5951.9549.2251.1746.4846.3643.9142.32 |
组别 | 动物数 | 给药剂量(mg/kg) | 瘤重(g) | 抑瘤率(%) |
空白对照组阳性对照组肿节风组白花蛇舌草组本发明药物组合物高剂量组本发明药物组合物中剂量组本发明药物组合物低剂量组 | 10101010101010 | -3014014014010570 | 1.98±0.750.46±0.34**##△△1.41±0.68*1.52±0.65*0.80±0.52**##△△0.97±0.59**##△△1.12±0.64**#△ | -76.7728.7923.2359.6051.0143.43 |
组别 | 动物数 | 给药剂量(mg/kg) | 生存天数 | 生命延长率(%) |
空白对照组阳性对照组肿节风组白花蛇舌草组本发明组合物高剂量组本发明组合物中剂量组本发明组合物低剂量组 | 10101010101010 | -3014014014010570 | 13.00±3.020.0±4.20**##△△15.00±2.00*14.80±2.10*19.2±2.50**##△△18.3±1.80**##△△17.5±2.30**##△ | -53.8515.3813.8547.6940.7734.62 |
组别 | 给药剂量(mg/kg) | 瘤重(g) | 抑瘤率(%) | 增效率(%) |
空白对照组Fu+肿节风组Fu+白花蛇舌草组Fu+本发明药物组合物高剂量组Fu+本发明药物组合物中剂量组Fu+本发明药物组合物低剂量组Fu组 | -14014014010570- | 2.32±0.590.72±0.23*0.75±0.34*0.51±0.31**##△△0.55±0.29**##△0.64±0.41**#△0.92±0.37 | -68.9767.6778.0276.2972.4160.34 | -21.7418.4844.5740.2230.43- |
组别 | 给药剂量(mg/kg) | 瘤重(g) | 抑瘤率(%) | 增效率(%) |
空白对照组60Co+肿节风组60Co+白花蛇舌草组60Co+本发明药物组合物高剂量组60Co+本发明药物组合物中剂量组60Co+本发明药物组合物低剂量组60Co | -140140140105700.05Gy/min | 2.56±0.961.77±0.57*1.82±0.64*1.17±0.46**#△△1.25±0.68**##△△1.32±0.75*#△2.08±0.87 | -30.8628.9154.3051.1748.4418.75 | -14.9012.5043.7539.9036.54- |
组别 | 给药剂量(mg/kg) | 平均瘤重(g) | 抑瘤率(%) | 增效率(%) | WBC(×109) | 脾指数 |
空白对照组阳性对照组CTX+肿节风组CTX+白花蛇舌草组CTX+本发明药物组合物高剂量组CTX+本发明药物组合物中剂量组CTX+本发明药物组合物低剂量组 | -3014014014010570 | 2.54±0.651.40±0.57*1.20±0.41**#1.32±0.25**#0.72±0.45##&$0.85±0.30#&$0.91±0.16#&$ | -39.2552.7**#46.74**#68.54##&$66.25#&$64.02#&$ | --27.1519.5351.2347.3244.15 | 8.87±2.173.42±1.17*6.26±1.79**#6.50±1.22**#8.11±1.54##&$7.84±1.82#&$7.25±1.49#&$ | 26.12±4.5010.37±2.26*15.36±2.54**#15.97±2.13**#22.14±4.22##&$21.10±3.57#&$19.33±4.21#&$ |
试管号 | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
本发明药物组合物注射液(ml)生理盐水(ml)蒸馏水(ml)2%红细胞悬液(ml) | 0.12.4-2.5 | 0.22.3-2.5 | 0.32.2-2.5 | 0.42.1-2.5 | 0.52.0-2.5 | -2.5-2.5 | --2.52.5 |
批次 | 药材(kg) | 提取物(kg) | 得率(%) | 异秦皮啶含量(%) | 反丁烯二酸含量(%) |
1234平均 | 5050505050 | 5.7017.9023.1011.1514.46 | 2.241.882.121.922.04 | 0.1030.1120.1090.1220.112 | 0.0220.0280.0270.0260.026 |
批次 | 药材(kg) | 提取物(kg) | 得率(%) | 总黄酮含量(%) |
1234平均 | 1010101010 | 0.0780.1240.1030.1820.122 | 0.780.951.031.441.05 | 65.458.762.354.560.2 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200610142637 CN100482266C (zh) | 2005-10-26 | 2006-10-25 | 一种由肿节风和白花蛇舌草制成的药物组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510104347 | 2005-10-26 | ||
CN200510104347.1 | 2005-10-26 | ||
CN 200610142637 CN100482266C (zh) | 2005-10-26 | 2006-10-25 | 一种由肿节风和白花蛇舌草制成的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1954870A true CN1954870A (zh) | 2007-05-02 |
CN100482266C CN100482266C (zh) | 2009-04-29 |
Family
ID=38062542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200610142637 Expired - Fee Related CN100482266C (zh) | 2005-10-26 | 2006-10-25 | 一种由肿节风和白花蛇舌草制成的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100482266C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106267029A (zh) * | 2016-10-12 | 2017-01-04 | 南宁多灵生物科技有限公司 | 一种治疗卵巢癌的中药组合物 |
CN106309749A (zh) * | 2016-10-12 | 2017-01-11 | 南宁多灵生物科技有限公司 | 一种治疗***的中药 |
CN106421386A (zh) * | 2016-10-13 | 2017-02-22 | 南宁多灵生物科技有限公司 | 一种治疗食管癌的中药 |
-
2006
- 2006-10-25 CN CN 200610142637 patent/CN100482266C/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106267029A (zh) * | 2016-10-12 | 2017-01-04 | 南宁多灵生物科技有限公司 | 一种治疗卵巢癌的中药组合物 |
CN106309749A (zh) * | 2016-10-12 | 2017-01-11 | 南宁多灵生物科技有限公司 | 一种治疗***的中药 |
CN106421386A (zh) * | 2016-10-13 | 2017-02-22 | 南宁多灵生物科技有限公司 | 一种治疗食管癌的中药 |
Also Published As
Publication number | Publication date |
---|---|
CN100482266C (zh) | 2009-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1954840A (zh) | 一种由绞股蓝、西洋参和黄芪制成的药物组合物 | |
CN1748765A (zh) | 一种具有通便排毒、减肥降脂功能的组合物及制备方法 | |
CN1245198C (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN1931236A (zh) | 一种由丹参和红景天制成的药物组合物 | |
CN101062084A (zh) | 一种抗肝炎的药物组合物 | |
CN1879688A (zh) | 风热清制剂及其制备方法和质量控制方法 | |
CN1923241A (zh) | 包括淫羊藿提取物、钩藤提取物、天麻素的药物组合物及其制备方法和应用 | |
CN1954870A (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN1954849A (zh) | 一种白花蛇舌草、人参和黄芪配伍的抗肿瘤的药物组合物 | |
CN1947747A (zh) | 由木犀草素和连翘制成的药物组合物及其制备方法和用途 | |
CN101041004A (zh) | 一种新的抗肿瘤复方药物 | |
CN100341492C (zh) | 一种参芪降糖软胶囊及其制备检测方法 | |
CN1947749A (zh) | 一种由头花蓼和茯苓制成的药物组合物 | |
CN1931233A (zh) | 一种用于治疗心脑血管疾病的丹参和淫羊藿的药用组合物 | |
CN1954838A (zh) | 一种抗肿瘤的药物组合物 | |
CN1939417A (zh) | 北豆根与金果榄或其提取物的药物组合物 | |
CN101049293A (zh) | 乙酰半胱氨酸或其药用盐和细辛脑的药物组合物 | |
CN1954839A (zh) | 由通关藤、人参和黄芪制成的药物组合物 | |
CN101073611A (zh) | 一种抗肿瘤的药物组合物 | |
CN101028336A (zh) | 一种头花蓼和独一味的药物组合物 | |
CN101062027A (zh) | 牛磺酸和治疗心脑血管疾病的药物的组合物 | |
CN1931216A (zh) | 一种由红花与红景天制成的药物组合物 | |
CN101049355A (zh) | 一种由红花与山楂叶制成的药物组合物 | |
CN1947783A (zh) | 一种头花蓼复方药物组合物及其制备方法和用途 | |
CN101040886A (zh) | 灯盏花和丹参酮ⅱa磺酸钠的药用组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: XUAN ZHU SHANDONG MEDICINE TECHNOLOGY CO. Free format text: FORMER OWNER: HUANG ZHENHUA Effective date: 20080516 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080516 Address after: Tianchen Avenue Ji'nan High-tech Development Zone in Shandong province No. 2518 post encoding: 250101 Applicant after: Shandong Xuanzhu Medical Technology Co., Ltd. Address before: Post encoding No. 2518 block A, Dongchen street, Ji'nan high tech Development Zone in Shandong Province: 250101 Applicant before: Huang Zhenhua |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAIAN SUSHI TECHNOLOGY TRANSFORMATION CENTER CO., Free format text: FORMER OWNER: SHANDONG XUANZHU MEDICAL TECHNOLOGY CO., LTD. Effective date: 20130930 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 226601 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130930 Address after: 226601 No. 8 Yingbin Road, software park, Haian County, Jiangsu Province Patentee after: Haian Su Fu Technology Transfer Center Co., Ltd. Address before: Tianchen Avenue in Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518 Patentee before: Shandong Xuanzhu Medical Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090429 Termination date: 20191025 |
|
CF01 | Termination of patent right due to non-payment of annual fee |